Australia: Current Position and Key Success Factors
|
|
- Donald Perry
- 7 years ago
- Views:
Transcription
1 Competitive Positioning Strategies for Australian Biotech Companies A Road Map to Achieve Competitive Position in the Global Biotech Marketplace Part III Australia: Current Position and Key Success Factors The following article analyzes the biotechnology market in Australia and discusses key success factors as building blocks for success. All revenues in this session are presented in US dollars, unless stated otherwise. All conversions have been undertaken at a fixed rate of Australian dollar (AUD) to US$1. 1. Market Overview Australia s strengths in biotech research include agriculture and medical research in general, but particularly immunology and vaccines, stem cells, proteomics, and medical devices. Though its research base is not large, Australia carries out high-quality research. Being an emerging industry, Australian biotechnology does not have many commercialized products. However, many products are in research pipelines and are likely to hit the market only in the next 5 10 years. Research is conducted mostly by universities and the Commonwealth Science and Industry Research Organization (CSIRO). Core biotechnology companies also perform research at their own or affiliated facilities. There is close co-operation between public sector research and the private sector in Australia, as evident from the participation and investment by private companies in the Co-operative Research Centers (CRCs) at the universities and partnership arrangements with the CSIRO. The number of spin-off companies (about 40 percent of all start-ups) is also indicative of this co-operation. Biotechnology Australia (a collaboration of five Commonwealth Government departments) is the key agency that coordinates the Commonwealth s activities in biotechnology and was established at the Commonwealth Budget announcement. In 2000, Biotechnology Australia launched a National Biotechnology Strategy (NBS) that directs the Government s activities in the sector. The Australian biotech industry comprises around 500 companies. There are around 280core biotech and 220 related biotech companies in Australia. In 2001, 67 biotech companies were listed in the Australia Stock Exchange (ASX) and 40 of them were core biotechnology companies. Most of these companies are of small to medium size but possess a good amount of intellectual property. Funding for these companies is mainly from private placements, the government, and the stock market. The Australian biotech industry has excellent potential and is likely to emerge as a significant player internationally, at least in niche markets in the future. 862 APBN Vol. 7 No
2 2. Sectors of Activity (Medical/Ag/Industrial) The biotechnology segments of Australia include agri-food; genomics, proteomics, bioinformatics, human health and therapeutics (includes biopharmaceuticals and diagnostics), devices and services, and environment and biochemical. Chart 1 presents distribution of core biotech companies by sector in Australia in 2002 Chart 1 Total Biotechnology Market: Distribution of Biotech Companies by Sector (Australia), Genomics, Proteomics & Bioinformatics 15% Human health and Therapeutics (Includes Biopharmaceuticals) 41% Devices, Diagnostics & Services 20% Environment & Biochemical 5% Agri-food 19% Source: Frost & Sullivan Agri-Food Historically, Australia has been very strong in agricultural and related industries. The quick and effective adoption of biotechnology has made a big difference to the Australian agri-food industry. Biotechnology is used to improve yield and quality of crops and livestock and also focuses on viticulture, fisheries, cotton, and beef industries. Researchers are developing biopesticides, bioherbicides, and biofertilizers using biotechnology. Genomics, Proteomics, and Bioinformatics Australia has many claims to fame in these areas. Dr. Marc Wilkins of Sydney-based Proteome Systems coined the term proteomics ; the first protein sequencer was developed in Australia. Australian companies have developed successful platform technologies and have generated international interest. The Federal and State governments are very active in genomics and proteomics research. The CSIRO focuses on functional genomics, discovery, and proteomics. The Garvan Institute of Medical Research s asthma and arthritis research program has developed a genomics facility with high-density microarray technology to search for genes involved in arthritis and asthma. Some of the major facilities are Australian Proteome Analysis Facility, Australian Genome Research Facility, Australian Phenomics Facility, Australian Synchrotron Research Program, and the Nanostructural Analysis Network Organization. Some of the private players include Proteome Systems, Autogen Limited, and Bionomics. Human Health and Therapeutics Australia has gained a good reputation in this area with high quality research work and a history of innovation. Research is being carried out on a range of diseases, clinical conditions, and technologies. This category consists of drug discovery companies besides those companies that are developing other forms of therapeutics including vaccines, specialized drug delivery systems, cell and tissue engineering, stem cellbased therapies, and genetic engineering. Of the 67 biotech companies listed in ASX, 32 are into drug discovery. Many universities and research institutes also focus on this segment. Some of the research institutions where medical research is being carried out are the Garvan Research Institute of Medical Research, Walter and Eliza Hall Institute of Medical Research, Baker Medical Research Institute, Austin Research Center, Howard Florey Institute, and Queensland Institute for Medical Research. The CSIRO along with around 20 CRCs also conducts extensive medical research. Medical Devices and Diagnostics There are around 500 companies in the medical devices and diagnostics industry. The industry directly employs almost 10,000 people and has local sales worth about $1.12 billion (AUD2 billion). Approximately 70 percent of sales are made to the public sector and more than 85 percent of devices and diagnostics used in Australia are imported. About 60 percent of these come from the United States. APBN Vol. 7 No
3 Environment and Biochemicals Australia s biotechnology industry has been successful in terms of developing innovative environmental applications. The environmental industry has competitive sectors such as rehabilitation and remediation of mining and industrial sites, wastewater treatment, and monitoring equipment. Fields of activity in Australia include innovative waste management, pest and weed control, bioremediation, water quality, and environmental monitoring. Expertise in areas such as agriculture and the comparatively low engineering costs have aided the development of environmental biotechnology. The South Australian Research and Development Institute (SARDI), and CSIRO conduct research in this area. Some of the important companies in this segment are EcoPro, Genesearch Pty Ltd, and Ecogrow. 3. Key Success Factors The following section discusses the key building blocks that are likely to enable successful future growth of the biotech industry in Australia the role played by the government, the regulatory infrastructure of the country, the biotech hubs in the country, human resources, and funding. 3.1 Role of the Government The Federal Government of Australia has promoted biotechnology realizing its potential to help the economy, boost social growth, and improve public health. The state governments are also very supportive of the biotech industry with some announcing their own biotech policies and generous funding programs. The Federal Government has created a framework for the growth of biotech in Australia. Initiatives to boost research and development through tax concessions, research funding and a network of tertiary institutions have created a vibrant industry. The Wills Report (March 1998) recommended the government to initiate closer interaction between industry, academic research organizations and the government. The report also recommended increasing the funding for academic research. Based on the recommendations, the Federal Government announced a doubling of the base funding for the National Health and Medical Research Council (NHMRC) over the next six years to $ million (AUD614.0 million). Biotechnology Australia was established in May 1999 to coordinate the involvement of the Commonwealth Government in non-regulatory aspects of biotechnology and to develop a National Biotechnology Strategy (NBS). The NBS was launched in July The NBS had an allocation of $17.15 million (AUD30.5 million) for the period , including $11.25 million (AUD20.0 million) for the establishment of a Biotechnology Innovation Fund (BIF) to assist with the commercialization of Australian biotechnology research at the critical proof-of-concept stage. The 2001 Budget included allocations of a further $11.25 million (AUD20.0 million) to the BIF and $26.15 million (AUD46.5 million) over five years to the Biotechnology Center of Excellence. The following are the initiatives of Biotechnology Australia as part of the NBS: Biotechnology Center of Excellence Initiative Biotechnology Intellectual Property Management Public Awareness Program Biotechnology Online for Secondary Schools The Backing Australia s Ability (BAA) is a government initiative that builds on the existing substantial Commonwealth support for innovation by boosting funding to key areas and introducing significant new initiatives. The BAA provides $1.69 billion (AUD2.9 billion) as additional funding over five years, for promoting technologies such as information technology and biotechnology. Some key aims of the NBS are to strengthen Australia s research capability, ensure flow of new ideas that underpin innovation, create critical mass in leading research fields, and build competitive advantage in Information and Communication Technologies (ICT) and biotechnology. The NBS provides significant new investment in these areas and tax incentives to ensure that Australia s research base remains strong and internationally competitive. 864 APBN Vol. 7 No
4 3.2 Regulatory Structure Australia has a well-structured and transparent regulatory regime in place. The gene technology regulations have roughly followed the US model, which helps in conducting business between the two countries. Australia is a participant in many international forums related to biotechnology and pharmaceuticals. The Therapeutic Goods Administration has signed a memorandum of understanding with the US FDA to permit organizations to exchange information on Good Manufacturing Practices (GMP) inspections of pharmaceuticals facilities. The main regulators are: Therapeutic Goods Administration (TGA) Office of the Gene Technology Regulator (OGTR) Food Standards Australia New Zealand (FSANZ) Australian Competition and Consumer Commission (ACCC) Australian Quarantine and Inspection Service (AQIS) National Occupational Health and Safety Commission (NOHSC) National Registration Authority (NRA) The Genetic Manipulation Advisory Committee (GMAC) Intellectual Property Regulations Australia s intellectual property regime complies with the WTO standards. In fact, Australia was the first country in the world to be granted a valid patent for a living organism in A wide range of biological materials and technical processes can be patented in Australia. The IP Australia is the Federal Government agency that grants rights in patents, trademarks, and designs. IP Australia controls the Patent, Designs, and Trademarks offices. 3.3 Geographical Hubs in the Country All the states and territories of Australia promote biotechnology. The Federal Government has encouraged the wide acceptance of biotechnology as a thrust area for socio-economic growth and has aided it with encouraging policies and generous economic grants. However, local academic and business interests have played a key role in the biotechnology adoption process. Concentration of companies across states varies, depending on various factors such as the academic environment, financial incentives offered by the state, and logistics. States vie with one another in promoting themselves as the best destination for biotech investments and offer substantial funding to start-ups. State assistance generally takes the form of grants, funds, and infrastructure assistance but states are also increasingly offering commercialization and networking assistance to companies. Most of the biotechnology activities are concentrated in the following states: Victoria New South Wales (NSW) Queensland Western Australia (WA) Australian Capital Territory (ACT) APBN Vol. 7 No
5 3.4 Human Resources The availability of qualified human resources is a prerequisite for ensuring a competitive position within the biotech industry, which is knowledge-intensive. Australia has a good number of graduates qualified in biotechnology and allied subjects. This is made possible by the many biotechnology courses introduced by the Australian universities. According to Ernst & Young/Freehills/ISR survey and research data 2001, there are in excess of 5700 full-time equivalent employees in the biotechnology industry, representing a growth of 46 percent since This figure does not include employees in supporting industries such as contract research and those in universities and research institutes. 3.5 Funding of Biotechnology Ventures in Australia Government Funding Both Commonwealth and state governments fund the biotechnology industry in Australia. States compete to attract knowledge industry companies by offering financial incentives and funding schemes to biotechnology companies. To enable companies overcome shortage of capital, programs such as the Innovation Investment Fund (IIF) and the Biotechnology Innovation Fund (BIF) were set up. The Federal Government spends around $176 million (AUD300 million) annually on biotech R&D through various agencies. Venture Capital Investment The Australian biotechnology industry has not been very successful in attracting seed and start-up venture capital. Unlike areas such as information technology, biotechnology is a highrisk area where investments are generally long-term. This factor combined with the high volatility of biotech stocks has contributed to the shortage of venture capital. Australia s capital gains tax structure was another impediment to venture capital partnerships and foreign investment in biotech start-ups. According to the Australian Bureau of Statistics, only five percent of the country s $2.86- billion (AUD4.9-billion) venture capital investment was for the biotechnology sector in However, recent legislative changes aim to remove some of these hurdles. This should augur well for the funds-starved biotech companies. Australia s leading lifesciences investors are BioTech Capital, Macquarie Bank, Rothschild Biosciences Managers Limited, and Queensland Investment Corporation. Upcoming... Vol 7 No 14 Part IV: Competitive Positioning Strategies and Road Map 866 APBN Vol. 7 No
BOOSTING THE COMMERCIAL RETURNS FROM RESEARCH
BOOSTING THE COMMERCIAL RETURNS FROM RESEARCH Submission in response to the Discussion Paper November 2014 Page 1 ABOUT RESEARCH AUSTRALIA is an alliance of 160 members and supporters advocating for health
More informationA vaccine for rheumatoid arthritis
A vaccine for rheumatoid arthritis Professor Ranjeny Thomas Founder and Director of Dendright Pty Limited Head, Autoimmunity Division, Diamantina Institute, The University of Queensland About Dendright
More informationProfile of Biomedical Research and Biotechnology Commercialization. Washington-Baltimore Consolidated Metropolitan Statistical Area
Profile of Biomedical Research and Biotechnology Commercialization Washington-Baltimore Consolidated Metropolitan Statistical Area Overview and History of Biotechnology in Washington-Baltimore The Washington,
More informationProfile of Biomedical Research and Biotechnology Commercialization. San Francisco Oakland San Jose Consolidated Metropolitan Statistical Area
Profile of Biomedical Research and Biotechnology Commercialization San Oakland San Jose Consolidated Metropolitan Statistical Area Overview and History of Biotechnology in San The San Bay area is in many
More informationVenture Capital in Australia
Venture Capital in Australia Venture Capital in Australia Australia offers attractive investment opportunities and significant early-stage investment support. Innovation is a key driver of economic performance.
More informationThe Commercialization of Technology Concepts into Medical Products
The Commercialization of Technology Concepts into Medical Products Kevin J. Scanlon, Ph.D. New Zealand 2006 International BioScience Overview Pharmaceutical Industry Biotechnology Startups Investment Community
More informationTHE PRODUCTIVITY COMMISSION EVALUATION OF THE PHARMACEUTICALS INDUSTRY INVESTMENT PROGRAM THE VICTORIAN GOVERNMENT POLICY CONTRIBUTION
THE PRODUCTIVITY COMMISSION EVALUATION OF THE PHARMACEUTICALS INDUSTRY INVESTMENT PROGRAM THE VICTORIAN GOVERNMENT POLICY CONTRIBUTION OCTOBER 2002 1 CONTENTS Executive summary 3 PIIP replacement 3 International
More informationIntroduction. The Healthcare Sector in Asia - Current Situation. Projected Healthcare Expenditure
Policy Issues in the Economics and Financing of Medical Technology in the Asia-Pacific Region Dr KAI HONG PHUA Joint Professor Yong Loo Lin School of Medicine and Lee Kuan Yew School of Public Policy National
More informationLocation for Trials- Global Considerations A Pharma Perspective. Carlo Maccarrone Assoc. Director, Clinical Research GSK Australia 7 May 2014
Location for Trials- Global Considerations A Pharma Perspective Carlo Maccarrone Assoc. Director, Clinical Research GSK Australia 7 May 2014 Why Choose Australia for Clinical Trials? What is he saying
More informationThe Current Economic Situation of Research Australia
EDITION 3: RESEARCH Summary Australia has roughly the same proportion of researchers in its workforce as the U.S. and major European countries, but a far lower proportion than Scandinavian countries. R&D
More informationManufacturing CUSTOM CHEMICALS AND SERVICES, SUPPORTING SCIENTIFIC ADVANCES FOR HUMAN HEALTH
Manufacturing CUSTOM CHEMICALS AND SERVICES, SUPPORTING SCIENTIFIC ADVANCES FOR HUMAN HEALTH VWR enables the advancement of science by providing high-quality chemicals and services, customized to your
More information19 October 2006. Company Announcement Office Bendigo Stock Exchange PO Box 191 Flinders Lane, Melbourne Vic 8009. By email; announcements@bsx.com.
19 October 2006 Company Announcement Office Bendigo Stock Exchange PO Box 191 Flinders Lane, Melbourne Vic 8009 By email; announcements@bsx.com.au RE: Announcement by State Development Fund Limited Please
More informationTRANSATLANTIC TRADE AND INVESTMENT PARTNERSHIP
DISCLAIMER: The EU reserves the right to make subsequent modifications to this text and to complement its proposals at a later stage, by modifying, supplementing or withdrawing all, or any part, at any
More informationLIFE SCIENCES QUEENSLAND LIMITED (LSQ) Mario Pennisi CEO. @LSQld
LIFE SCIENCES QUEENSLAND LIMITED (LSQ) Mario Pennisi CEO @LSQld LEADING DESTINATION FOR CLINICAL RESEARCH INVESTORS IN QLD INCLUDE: LIFE SCIENCES IN QLD ~300 companies in life sciences ~$5B invested by
More information75 YEARS OF WORKING TO BUILD A HEALTHY AUSTRALIA NHMRC
75 YEARS OF WORKING TO BUILD A HEALTHY AUSTRALIA NHMRC Research Funding Facts Book 2011 75 YEARS OF WORKING TO BUILD A HEALTHY AUSTRALIA NHMRC Research Funding Facts Book 2011 Australian Government 2011
More informationAustralia Life Sciences Market
Australia Life Sciences Market Monique Roos, Commercial Specialist U.S. Commercial Service, Sydney, Australia November 2014 Geographical Size Population Density More than 80% of population in this ring
More informationMYRIAD, HITACHI, ORACLE & FRIEDLI JOIN FORCES TO MAP THE ENTIRE HUMAN PROTEOME
FOR IMMEDIATE RELEASE MYRIAD, HITACHI, ORACLE & FRIEDLI JOIN FORCES TO MAP THE ENTIRE HUMAN PROTEOME - $185 Million Collaboration to Determine All Human Protein Interactions And Decipher Biochemical Pathways
More informationChemistry and Biomolecular Sciences: study and career opportunities
Chemistry and Biomolecular Sciences: study and career opportunities Department of Chemistry and Biomolecular Sciences, CBMS A/Prof Joanne Jamie, Deputy Head Who we are (CBMS) Study programs Facilities
More informationThe Board reviews risks to the Company s business plan at its scheduled meetings.
Pharmaxis Ltd 1. Board responsibility The Pharmaxis Board is responsible for ensuring the Company establishes and maintains a risk management framework for the oversight and management of risk. The Board
More informationPRIME MINISTER S SCIENCE, ENGINEERING AND INNOVATION COUNCIL OPPORTUNITIES TO PRODUCE A VIBRANT AUSTRALIAN SOFTWARE INDUSTRY
PRIME MINISTER S SCIENCE, ENGINEERING AND INNOVATION COUNCIL FIRST MEETING, 29 May 1998 Canberra OPPORTUNITIES TO PRODUCE A VIBRANT AUSTRALIAN SOFTWARE INDUSTRY - REPORT OF THE SOFTWARE WORKING GROUP Summary
More informationDepartment of Microbiology Vidyasagar University Midnapore - 721 102 West Bengal
S'yllabus for the I 'year FG Diploma Course in QUALITY CONTROL AND ASSURANCE IN MICROBIAL TECHNOLOGY (Semester Based: 400 marks in two semesters) Department of Microbiology Vidyasagar University Midnapore
More informationCotton industry biosecurity statement 2014-2015
Cotton industry biosecurity statement 2014-2015 Cotton Australia recognises the need for the cotton industry to work with the federal, state and territory governments to help reduce the potential for incursions
More informationThe Australian Capital Territory in the Asian Century
The Australian Capital Territory in the Asian Century August 2013 SUMMARY The Australian Government s Australia in the Asian Century White Paper has given added impetus to action the ACT government is
More informationR&D Tax Incentive. Research Service Providers. Linking business with research
R&D Tax Incentive Research Service Providers Linking business with research 1 Contents What are Research Service Providers (RSPs)? 3 The R&D Tax Incentive 4 Why do R&D? And how? 6 RSPs the benefits 7 How
More informationThe Biotech Business Life Cycle. The Lawyer s Role as Counselor and Advisor
The Biotech Business Life Cycle and The Lawyer s Role as Counselor and Advisor ASU February 15, 2010 1 BIOTECH BUSINESS CYCLE AN INTERDISCIPLINARY APPROACH TO LEGAL REPRESENTATION Intellectual Property
More informationDr Alexander Henzing
Horizon 2020 Health, Demographic Change & Wellbeing EU funding, research and collaboration opportunities for 2016/17 Innovate UK funding opportunities in omics, bridging health and life sciences Dr Alexander
More information&2$*5HODWHG5HIRUPV (OHFWULFLW\*DV:DWHU5RDG 7UDQVSRUW
&2$*5HODWHG5HIRUPV (OHFWULFLW\*DV:DWHU5RDG 7UDQVSRUW The major infrastructure areas of electricity, gas, water and road transport are subject to reform requirements set out in separate Inter-Governmental
More informationAustralian Dental Association Inc. Cooperative Research Centres Programme Review
Australian Dental Association Inc. Cooperative Research Centres Programme Review Australian Dental Association Inc. 14 16 Chandos Street St Leonards NSW 2065 PO Box 520 St Leonards NSW 1590 Tel: (02) 9906
More informationA Texas Life Science Perspective. Thomas R. Kowalski President Texas Healthcare and Bioscience Institute
A Texas Life Science Perspective Thomas R. Kowalski President Texas Healthcare and Bioscience Institute 1 What is THBI? The Texas Healthcare and Bioscience Institute (THBI) is a non-profit, public policy
More informationHealth and Medical Research Australia 2006-2011
ACCELERATING DISCOVERY AND CAPTURING THE RETURNS A 5-YEAR PLAN FOR INVESTMENT IN HEALTH AND MEDICAL RESEARCH IN AUSTRALIA 2006-2011 Response to the Investment Review of Health and Medical Research: Sustaining
More informationCALIFORNIA STATE UNIVERSITY CHANNEL ISLANDS
CALIFORNIA STATE UNIVERSITY CHANNEL ISLANDS PROGRAM MODIFICATION DATE: 12.06.06 PROGRAM AREA: BIOLOGY AND BUSINESS AND ECONOMICS SEMESTER /YEAR FIRST EFFECTED: FALL 2007 Please use the following format
More informationInquiry into educational opportunities for Aboriginal and Torres Strait Islander students Submission 18
Introduction The National Catholic Education Commission (NCEC) welcomes the opportunity to provide a submission as part of the House of Representatives Standing Committee on Indigenous Affairs inquiry
More informationEmerging Clinical Sites: India and China. Patrycja Doba, Clinical Research Coordinator
Emerging Clinical Sites: India and China Patrycja Doba, Clinical Research Coordinator Overview 1. Outsourcing trends in Pharmaceutical Industry 2. Reasons for outsourcing 3. The most outsourced activity
More informationPROMETIC LIFE SCIENCES INC.
PROMETIC LIFE SCIENCES INC. Investor Update July to September 2002 This present release must be considered as the quarterly report to shareholders. 1. Letter to Shareholders Dated November 21, 2002 2.
More informationNSW Branch Committee MEMBER PROFILES
MEMBER PROFILES www.ausbiotech.org AusBiotech is Australia's Biotechnology Industry Organisation, which represents over 2,550 members, covering the human health, agricultural, medical device, bioinformatics,
More informationSmall business guide to trade practices compliance programs. April 2006
Small business guide to trade practices compliance programs April 2006 Commonwealth of Australia 2006 ISBN 1 920702 93 8 This work is copyright. Apart from any use permitted under the Copyright Act 1968
More informationPart 3 Medical Officer (MO) Work Level Standards
Part 3 Medical Officer (MO) Work Level Standards MEDICAL OFFICER-CLASSES 1 6 GROUP STANDARD The work of positions in this group involves the application of professional medical knowledge and experience
More informationMTAA KEY POLICIES FOR 2013 ELECTION. 1 February 2013. 1. Improving reimbursement of medical technologies by private health insurance
MTAA KEY POLICIES FOR 2013 ELECTION 1 February 2013 1. Improving reimbursement of medical technologies by private health insurance Medical technology is not funded by the Commonwealth Government in the
More informationSUBMISSION TO PRODUCTIVITY COMMISSION REVIEW OF MUTUAL RECOGNITION SCHEMES JANUARY 2015
QUEENSLAND COLLEGE OF TEACHERS SUBMISSION TO PRODUCTIVITY COMMISSION REVIEW OF MUTUAL RECOGNITION SCHEMES JANUARY 2015 BACKGROUND The Queensland College of Teachers ( the QCT ) was established in January
More informationSPONSORSHIP BUSINESS PLAN
11 th AUSTRALIAN INTERNATIONAL PEPTIDE CONFERENCE Kingscliff, NSW, Australia 25th - 30th October 2015 SPONSORSHIP BUSINESS PLAN The Australian Peptide Association Organising Committee invites you to partner
More informationBACKING AUSTRALIA S ABILITY AN INNOVATION ACTION PLAN FOR THE FUTURE
BACKING AUSTRALIA S ABILITY AN INNOVATION ACTION PLAN FOR THE FUTURE 2 B A C K I N G A U S T R A L I A S A B I L I T Y Commonwealth of Australia 2001 ISR 2000/223 ISBN 0 642 72133 5 This work is copyright.
More informationRising Concentration in Agricultural Input Industries Influences New Farm Technologies
DECEMBER 2012 VOLUME 10, ISSUE 4 FEATURE ARTICLE Rising Concentration in Agricultural Input Industries Influences New Farm Technologies Keith Fuglie kfuglie@ers.usda.gov Paul Heisey pheisey@ers.usda.gov
More informationProfile of Biomedical Research and Biotechnology Commercialization. San Diego Metropolitan Statistical Area
Profile of Biomedical Research and Biotechnology Commercialization San Diego Metropolitan Statistical Area Overview and History of Biotechnology in San Diego San Diego has a significant concentration of
More informationAustralian Government Response to the Senate Committee on Finance and Public Administration
Australian Government Response to the Senate Committee on Finance and Public Administration Australian Government Response to the Senate Committee on Finance and Public Administration Native Vegetation
More informationThe Regulatory Framework Gene Technology Act 2000 (Cth) and the Gene Technology Bill 2001 (WA)
For Who s Benefit? - Evaluating Genetically Modified Organisms in Western Australia from a Different Perspective Conference held by Conservation Council WA 10 October 2002 The Regulatory Framework Gene
More informationBIOSCIENCE 08 OKLAHOMA. Recent State Initiatives
BIOSCIENCE 08 OKLAHOMA The largest bioscience subsector in Oklahoma is research, testing, and medical laboratories (2,895 jobs). Total academic bioscience research expenditures in 2006 were $169 million,
More informationConstruction induction training - changes to regulations
Construction induction training - changes to regulations General information for industry The Occupational Safety and Health Regulations (1996) have changed to reflect the national approach to construction
More informationBudget priorities: cut company tax, invest in infrastructure and balance budget within five years.
Ai Group Survey Business Priorities for the 2014-15 Federal Budget Budget priorities: cut company tax, invest in infrastructure and balance budget within five years. 4 May 2014 The top three priorities
More informationBiotechnology and Life Science Marketing Services Mailing List and Data Card Order Form
C H I Cambridge Healthtech Institute s Biotechnology and Life Science Marketing Services Mailing List and Data Card Order Form Over 800,000 names segmented by scientific interest Featuring U.S and International
More informationValentina Gualato, Ph.D. Process Development Scientist
COMPANY PRESENTATION Quality and Innovation Valentina Gualato, Ph.D. Process Development Scientist MISSION areta international is a biotech company dedicated to the contract development and manufacturing
More informationThe Role of Government in Supporting Entrepreneurship & SME Development
The Role of Government in Supporting Entrepreneurship & SME Development Mohammed Bin Rashid Establishment For SME Development DUBAI SME 2011 Support for Entrepreneurship Why? Seed pipeline of future enterprises,
More informationAn Overview of the Life Sciences and Outsourcing Landscape in India: Spotlight on Bangalore
An Overview of the Life Sciences and Outsourcing Landscape in India: Spotlight on Bangalore A CanBiotech Report CanBiotech, 2007 1 An Overview of the Life Sciences and Outsourcing Landscape in India: Spotlight
More informationBachelor of Business International Event Management
Bachelor of Business International Event Unit name Aim Topics covered Level 1 BUS101 Accounting Fundamentals The aim of the unit is to provide students with the fundamental skills and knowledge to understand
More informationPest Management Sector Snapshot
Pest Management Sector Snapshot Sources: http://joboutlook.gov.au/occupation.aspx?search=keyword&tab=overview&cluster=&code=8419 http://www.aepma.com.au/ http://www.cpsisc.com.au/resource-centre/psug/imppestmanagement/pmintroduction
More informationPro Bono Practices and Opportunities in Australia
Pro Bono Practices and Opportunities in Australia Excerpt from: A Survey of Pro Bono Practices and Opportunities in Selected Jurisdictions September 2010 Prepared by Latham & Watkins LLP for the Pro Bono
More informationEdith Cowan University Faculty of Health, Engineering and Science Work Health and Safety Committee
PROCEDURES Title: PROCEDURES - HANDLING INFECTIOUS MATERIALS AND INFECTION CONTROL Descriptors: 1) 2) 3) 4) Category: OS&H Purpose Organisational Scope Policy Statement Definitions Principles Content References
More informationFACULTY OF MEDICAL SCIENCE
Doctor of Philosophy Program in Microbiology FACULTY OF MEDICAL SCIENCE Naresuan University 171 Doctor of Philosophy Program in Microbiology The time is critical now for graduate education and research
More informationMining Technology Services Industry
Knowledge Intensive Service Activities in the Mining Technology Services Industry in Australia A report prepared for the OECD KISA project 1 This report has been prepared by the Australian Government,
More informationTasmanian Department of Health and Human Service
Tasmanian Department of Health and Human Service Agency Health Professional Reference Group Allied Health Professional Workforce Planning Group Allied Health Professional Workforce Planning Project Audiology
More informationFLINDERS UNIVERSITY - NEW COURSE PROPOSAL FORM PART A COURSE INFORMATION (DOMESTIC) Professor Andrew Millington Date: 13.11.2012
1. CONTACT DETAILS AND AUTHORISATION 1.1 Contact Staff Member: 1.2 Endorsement by Dean of School: Name: Stephen Fildes Contact details: stephen.fildes@flinders.edu.au Phone: 1-2321 Name: Professor Andrew
More informationProfile of Biomedical Research and Biotechnology Commercialization. Boston-Worcester-Lawrence Consolidated Metropolitan Statistical Area
Profile of Biomedical Research and Biotechnology Commercialization Boston-Worcester-Lawrence Consolidated Metropolitan Statistical Area Overview and History of Biotechnology in Boston Along with San Francisco,
More informationK-12 Entrepreneurship Standards
competitiveness. The focus will be on business innovation, change and issues related to the United States, which has achieved its highest economic performance during the last 10 years by fostering and
More informationAMP to acquire 19.9% of China Life Pension Company
30 October 2014 AMP to acquire 19.9% of China Life Pension Company AMP Limited, Australia and New Zealand s leading independent wealth management business, announced it has agreed to acquire a 19.99 per
More informationBattelle Battelle s Technology Partnership Practice (TPP) Pharmaceutical Research and Manufacturers of America (PhRMA)
Every day, the people of Battelle apply science and technology to solving what matters most. At major technology centers and national laboratories around the world, Battelle conducts research and development,
More informationAn Introduction to Genomics and SAS Scientific Discovery Solutions
An Introduction to Genomics and SAS Scientific Discovery Solutions Dr Karen M Miller Product Manager Bioinformatics SAS EMEA 16.06.03 Copyright 2003, SAS Institute Inc. All rights reserved. 1 Overview!
More informationRoad map for establishing Technology & Innovation Support Centers (TISC)
Road map for establishing Technology & Innovation Support Centers (TISC) I. Background 1. Why: a. To allow users to benefit effectively from increased accessibility offered by internet searches (including
More informationSubmission by the Regional Universities Network (RUN) to the Inquiry into the Australian Innovation System
Submission by the Regional Universities Network (RUN) to the Inquiry into the Australian Innovation System Introduction For Australia to remain a prosperous nation with high standards of health and well-being,
More informationForeword. Closing the Gap in Indigenous Health Outcomes. Indigenous Early Childhood Development. Indigenous Economic Participation.
National Aboriginal and Torres Strait Islander Health Workforce Strategic Framework 2011 2015 Prepared for The Australian Health Ministers Advisory Council by the Aboriginal and Torres Strait Islander
More informationA Degree in Science is:
A Degree in Science is: Intellectually stimulating Can lead to a variety of careers: Scientific Research (with opportunities for working with animals) Teaching Science-related jobs Advisory Sales Patents..
More informationProduct Development Partnerships (PDPs): Overview
Product Development Partnerships (PDPs): Overview Product Development Boot Camp 6 November 2015 Dr. Ryan Wiley President Shift Health is a healthcare strategy consultancy devoted exclusively to healthcare
More informationFINANCIAL SYSTEM INQUIRY
FINANCIAL SYSTEM INQUIRY Second Round Submission- Promoting Innovation July 2014 Page 1 ABOUT RESEARCH AUSTRALIA is an alliance of 160 members and supporters advocating for health and medical research
More informationTherapeutic Goods Administration Orphan Drugs Program: Discussion paper
Therapeutic Goods Administration Orphan Drugs Program: Discussion paper Submission from the Clinical Oncology Society of Australia and Cancer Council Australia March 2015 The Clinical Oncology Society
More informationAccreditation Standards for Entry-Level. Occupational Therapy Education Programs PRELIMINARY CONSULTATION
Accreditation Standards for Entry-Level Occupational Therapy Education Programs PRELIMINARY CONSULTATION NOVEMBER 2012 Occupational Therapy Council (Australia & New Zealand) Ltd PO Box 959 South Perth
More informationCASUALTY CASUALTY INSURANCE SOLUTIONS
CASUALTY CASUALTY INSURANCE SOLUTIONS CONTENTS Casualty Insurance Solutions 03 Products and coverage extensions 04 Preferred industry segments 04 Casualty Capacity by NAIC code 05 About ACE 05 ACE Global
More informationAon Risk Solutions. Life Sciences Practice. Providing End-to-End Solutions for Life Sciences Companies. Risk. Reinsurance. Human Resources.
Aon Risk Solutions Life Sciences Practice Providing End-to-End Solutions for Life Sciences Companies Risk. Reinsurance. Human Resources. 1 The Life Cycle Risk Continuum An overview of industry-specific
More informationFuori EXPO Australia Agri-Food Investment Seminar
Fuori EXPO Australia Agri-Food Investment Seminar Australian agribusiness generates over AUS 150 billion annually, is innovative and is in big demand in Asia learn how Italian companies and researchers
More informationTrade Training Centres in Schools Programme
Trade Training Centres in Schools Programme Discussion Paper for Stakeholder Consultations February 2007 1 Contents Introduction...3 Overview...3 Programme objectives...4 Priorities...4 A partnership approach...5
More informationSMALL BUSINESS INNOVATION RESEARCH (SBIR) SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) GRANT APPLICATIONS
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES PHS 2015-2 OMNIBUS SOLICITATION OF THE NATIONAL INSTITUTES OF HEALTH, CENTERS FOR DISEASE CONTROL AND PREVENTION, FOOD AND DRUG ADMINISTRATION, AND ADMINISTRATION
More informationHow To Make A Drought Tolerant Corn
DROUGHT TOLERANT CORN STEVE PADGETTE JOHN GOETTE CHAN MAZOUR Forward Looking Statements Certain statements contained in this presentation are "forward-looking statements," such as statements concerning
More informationAchieving Regulatory Success: Areas of focus for biotechnology companies. Michael J. Schlosser, PhD, DABT April 21, 2013
Achieving Regulatory Success: Areas of focus for biotechnology companies Michael J. Schlosser, PhD, DABT April 21, 2013 Regulatory Success Outline Regulatory Initiatives Regulatory Science Pre-Regulatory
More informationComparative Study of Frameworks to protect the Long Term Interests of Pension Funds Investing in Public-Private Partnerships
EMAIL contact@fosterinfrastructure.com WEB www.fosterinfrastructure.com Comparative Study of Frameworks to protect the Long Term Interests of Pension Funds Investing in Public-Private Partnerships Pty
More informationWE RE HERE TO CHANGE BUSINESS ENERGY IN AUSTRALIA FOREVER.
BUSINESS ELECTRICITY CAN BE BETTER. MUCH BETTER. ERM POWER HAS BEEN A QUIET ACHIEVER IN THE ENERGY INDUSTRY FOR MORE THAN 30 YEARS. WE SPECIALISE IN SELLING ELECTRICITY TO BUSINESS CUSTOMERS AND HAVE GROWN
More informationCOOPERATIVE RESEARCH CENTRES PROGRAMME REVIEW
COOPERATIVE RESEARCH CENTRES PROGRAMME REVIEW Submission by November 2014 Page 1 ABOUT RESEARCH AUSTRALIA is an alliance of 160 members and supporters advocating for health and medical research in Australia.
More informationAFFITECH and XOMA Sign Antibody Collaboration and Cross-License Agreement
FOR IMMEDIATE RELEASE Ref 05AFF05 Contacts for Affitech: Contacts for XOMA Affitech (Norway): Investor Inquiries Dr. Martin Welschof Ellen M Martin Chief Executive Officer Kureczka/Martin Associates Phone:
More informationTECHNOLOGIES, PRODUCTS & SERVICES for MOLECULAR DIAGNOSTICS, MDx ABA 298
DIAGNOSTICS BUSINESS ANALYSIS SERIES: TECHNOLOGIES, PRODUCTS & SERVICES for MOLECULAR DIAGNOSTICS, MDx ABA 298 By ADAMS BUSINESS ASSOCIATES MAY 2014. May 2014 ABA 298 1 Technologies, Products & Services
More informationSENATE COMMUNITY AFFAIRS LEGISLATION COMMITTEE
SENATE COMMUNITY AFFAIRS LEGISLATION COMMITTEE Public Hearings: ADDITIONAL ESTIMATES FOR 2012-2013 Wednesday, 13 February to Thursday, 14 February 2013 Committee Room 2S1, Parliament House, Canberra ACT
More informationAustralia has the highest reported per capita incidence of asbestos-related disease in the world.
Australia has the highest reported per capita incidence of asbestos-related disease in the world. In the next 20 years, an estimated 30,000 to 40,000 Australians will be diagnosed with an asbestos-related
More information2 March 2015. Mutual Recognition Schemes Study Productivity Commission Locked Bag 2 Collins Street East MELBOURNE VIC 8003
2 March 2015 Mutual Recognition Schemes Study Productivity Commission Locked Bag 2 Collins Street East MELBOURNE VIC 8003 Sent via email to: mutual.recognition@pc.gov.au Dear Commissioner, Master Electricians
More informationAustralian Remote Renewables: Opportunities for Investment
Australian Remote Renewables: Opportunities for Investment The largely untapped remote clean energy market and funding support available from the Australian Government creates an attractive opportunity
More informationRemote microscope diagnostics: Improving Australia s diagnostic capacity and biosecurity
Remote microscope diagnostics: Improving Australia s diagnostic capacity and biosecurity MP Thompson 1,2, A Carmichael 2,5, S Shattuck 1, G Kong 2,4, D Peck 3, J La Salle 1 1 Michael.thompson@csiro.au,
More informationTHE NEW WAY IN PROFESSIONAL SERVICES
THE NEW WAY IN PROFESSIONAL SERVICES THE NEW WAY IN PROFESSIONAL SERVICES VALUE At Ash St. our absolute commitment is to client satisfaction in all aspects of our work including certainty around pricing.
More informationDr.ssa Maria Luisa Nolli CEO
IL RUOLO DELLE PICCOLE E MEDIE INDUSTRIE NELLA PROMOZIONE DELLA MEDICINA TRASLAZIONALE Quality and Innovation Dr.ssa Maria Luisa Nolli CEO INTRODUCTION ARETA INTERNATIONAL 12 years of experience in contract
More informationGuidelines and other health updates
HEALTH Inside: New privacy laws and their impact on research activities Queensland's biotechnology code The ACCC report to the Senate on health funds Guidelines and other health updates Partner Lionel
More informationSchool of Life Sciences. Taught Postgraduate Programmes
School of Life Sciences Taught Postgraduate Programmes Welcome to the School of Life Sciences The School of Life Sciences provides excellent teaching delivered by world-class academic researchers and external
More informationStatement of ethical principles for biotechnology in Victoria
Statement of ethical principles for biotechnology in Victoria Statement of ethical principles for biotechnology in Victoria Acknowledgments Published by the Public Health Group, Rural & Regional Health
More informationTECHNICAL UPDATE TAX INCENTIVES FOR INNOVATION LEGISLATION INTRODUCED
TECHNICAL UPDATE TAX INCENTIVES FOR INNOVATION LEGISLATION INTRODUCED THE FEDERAL GOVERNMENT HAS INTRODUCED LEGISLATION TO COMMENCE THE IMPLEMENTATION OF ITS INNOVATION STATEMENT OF DECEMBER 2015, WHICH
More informationComparing Chinese Investment into North America and Europe
Comparing Chinese Investment into North America and Europe 1 EXECUTIVE SUMMARY Chinese outbound foreign direct investment (OFDI) has grown rapidly in recent years and is increasingly flowing to high-income
More informationIndian Agrochemical Industry
Indian Agrochemical Industry Introduction. India is the fourth largest producer of agrochemicals globally, after United States, Japan and China. The agrochemicals industry is a significant industry for
More informationMessage from Administrator
ISSUE 6: NOVEMBER 2015 2012015 2015 Message from Administrator There has been much achieved over the past five months and I ll be pleased to welcome Paul Fletcher MP, Minister for Territories, Local Government
More information